Presenting features of COVID-19 in older people: relationships with frailty, inflammation and mortality

Introduction

As healthcare systems around the world start to respond to SARS-CoV-2, a major consideration is the apparent age-related heterogeneity in presentation, treatment responsiveness and clinical outcomes [1]. COVID-19 in older people, prima facie, may present in the absence of classical symptoms, progress more rapidly to severe disease, have poorer intensive care outcomes, longer inpatient stay and higher mortality [2, 3]. Nonetheless, questions remain as to which presenting features have greatest impact on these outcomes in older people. Recognising this may lead to better clinical care, as well as forming the basis for new services for older people after COVID-19.

Given this urgent need to understand COVID-19 in older people, we set out to describe the clinical, laboratory and radiological features in a series of older individuals hospitalised with COVID-19 in a large urban hospital.

Methods

Results

We identified 217 individuals aged ≥70 years hospitalised with COVID-19. Mean age of patients was 80 years (range 70 to 99 years), 62% were male and a range of pre-morbid frailty was identified (Table 1). The majority of patients had no formal package of community care (n=154, 71%) and 8 patients (4%) were admitted from residential care homes. 72 individuals (33%) were living with definite or probable dementia (Table 1).

On admission, symptoms of fever, dyspnoea and cough were common (n=157, 72%; n=143, 66%; n=130, 60% respectively) (Table 1). Symptoms of gastro-intestinal disturbance were less frequent (n=7, 3%). Some individuals were admitted without any of these cardinal COVID-19 symptoms (n=25, 12%), instead presenting with one or more frailty syndrome (reduced mobility, falls or delirium). Figure 1 details the combinations of presenting symptoms observed in our sample.

• Download figure
• Open in new tab

Fig. 1.

Venn diagram of common presenting clinical symptoms (a) and frailty syndromes (b) in hospitalised older adults with COVID-19.

There was a significant decrease in CRP and neutrophil: lymphocyte ratio with higher CFS scores (Table 2 and Figure 2).

• Download figure
• Open in new tab

Fig. 2.

Relationship between immune activity on hospitalisation by degree of frailty and possible divergent routes to mortality.

The contribution of demographic data, clinical presentation and inflammatory markers on admission to mortality was assessed in univariable and multivariable models (Table 3). There was an age-related increase in mortality (HR 1.1, 95% CI 1.0 to 1.1, p<0.01), but neither sex nor frailty was not associated with mortality (Table 3). Of classical COVID-19 symptoms, fever (HR 1.97, 95% CI 1.4 to 3.4, p=0.02) or dyspnoea (multivariable HR 2.0, 95% CI 1.2 to 3.3, p=0.01) at presentation were associated with increased mortality. For frailty syndromes, delirium was associated with mortality (HR 1.9, 95% CI 1.2 to 3.0, p<0.01) (Table 3). With rising CRP or higher neutrophil: lymphocyte ratio there was a corresponding increase in likelihood of death (Table 3).

High dependency unit level care and progression to non-invasive ventilation (NIV) or intubation demonstrated higher age-sex-frailty adjusted mortality (HR 3.5, 95% CI, 2.3 to 5.6, p<0.01). In terms of increased rehabilitation needs (evidence of cognitive or physical decline at discharge), only delirium was associated with new or worsening of cognitive impairment in models adjusted for age, sex, dementia and premorbid frailty (OR 44, 95% CI 7.4 to 260). No other admission parameters were associated with cognitive decline or physical decline at discharge, including premorbid dementia.

Discussion

Here, we describe clinical characteristics and outcomes of older adults admitted to a large London hospital in the first 100 days of the UK COVID-19 outbreak. Frailty syndromes were common presentations, sometimes in the absence of classical COVID-19 symptoms. Some presenting features – fever, dyspnoea, delirium – but not frailty, was associated with increased mortality. However, frailty was associated with a lower degree of inflammation on admission. Taken together, these results quantify the degree to which COVID-19 may present without cardinal symptoms as well as implicate a possible role for age-related changes in immunity (immunesenscence) in mediating the relationship between frailty and mortality.

Our findings should be treated with caution. Our data come from a single site in an urban population in the context of the UK National Health Service (NHS) undergoing restructuring to prepare for the COVID-19 pandemic, limiting generalisation to different health care systems. In particular, the need for ‘further rehabilitation on discharge’ will be specific to the local interface between secondary and community care. Furthermore, as a hospitalised cohort, clinical features and their relation to outcome might vary in population samples. Our measures of immune activity were derived from routinely available laboratory tests on presentation to acute care, rather than direct markers of immunesenescence that might have been available prior to infection. Nonetheless, we had the advantage of specialist geriatrician review of all electronic patient records, which allowed us to ascertain outcomes in near real-time.

Our data indicate that fever and dyspnoea may be important prognostic signs. The clinical significance of delirium has been observed in other COVID-19 cohorts, including from our own hospital [4, 5]. However, the inverse relationship between immune markers on admission and frailty has not previously been noted in COVID-19.

These findings add to the growing descriptive data characterising COVID-19 presentations in older adults [6, 7] and may help inform prognosis at the point of hospital admission. Overt inflammatory activation has been implicated in COVID-19 pathogenesis [8-11] but it is not clear the extent to which this might operate in older adults living with frailty. Frailty and chronic inflammation are linked to immunesenescence and may influence response to infection and subsequent immunity [12-14]. Our finding of lower levels of inflammation in frail patients supports the possibility that background frailty and immunesenescence could constrain the acute inflammation evident in COVID-19 (Figure 2). Whether this accounts for the apparent excess mortality in fitter patients remains speculative [15], though if borne out by further research, has implications for future therapeutic and vaccine strategies.

COVID-19 disproportionately affects older people, warranting a co-ordinated global response. Even in this early stage of understanding the disease, biological complexities that come with ageing are even more apparent in this population. This then becomes an opportunity, indeed a responsibility, for professionals with expertise in clinical and research practice in older people to intensify our efforts on COVID-19.

Declarations